Newsletter Tool

Editor’s Note: Fierce Biotech won't be publishing this Thursday and Friday in observance of the federal July 4th holiday. Enjoy the time off, and we'll be back in your inbox Monday, July 8.

Today’s Big News

Jul 3, 2024

GSK pays CureVac $430M for mRNA vaccines against flu and COVID—as partner lays off 30%

Radiopharma-focused Pentixapharm picks up Glycotope's discovery unit for preclinical cancer antibodies

Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial

Apollomics execs lead job cuts as cancer biotech ekes out cash

Featured

GSK pays CureVac $430M for mRNA vaccines against flu and COVID—as partner lays off 30%

By Nick Paul Taylor

GSK is paying 400 million euros upfront for full rights to CureVac’s mRNA vaccines against influenza and COVID-19. The mRNA specialist shared news of the deal alongside a restructuring that will put 30% of its employees out of work and extend its cash runway into 2028.

Radiopharma-focused Pentixapharm picks up Glycotope's discovery unit for preclinical cancer antibodies

By James Waldron

Radiopharmaceutical company Pentixapharm is picking up fellow Germany-based Glycotope's discovery unit for an undisclosed sum in order to double its pipeline courtesy of a portfolio of preclinical cancer antibodies.

Beacon attracts $170M series B to push eye disease gene therapy through late-stage trial

By James Waldron

Beacon Therapeutics has raised a $170 million series B, which the U.K.-based gene therapy biotech will use to push its eye disease candidates through clinical trials.

Apollomics execs lead job cuts as cancer biotech ekes out cash

By Nick Paul Taylor

Apollomics is cutting two executives loose and narrowing the focus of a key clinical trial to delay the date cash constraints could bring it crashing back down to earth.

Game on: Lilly's Alzheimer's drug Kisunla, a challenger to Biogen and Eisai's Leqembi, gains full FDA nod

By Angus Liu,Fraiser Kansteiner

After turning down Eli Lilly’s Alzheimer’s disease drug donanemab for an accelerated approval last year, the agency has now offered the anti-amyloid therapy, a competitor to Eisai and Biogen’s Leqembi, a full approval.

Masimo leaders, engineers threaten to walk if CEO Joe Kiani is ousted in proxy fight

By Conor Hale

Nearly 300 of Masimo's engineers and managers—as well as its COO—have signed letters saying they might follow the company's founder out the door.

China-made injectable PD-L1 drug flunks pivotal trial, forcing US partner to seek strategic options

By Angus Liu

The world’s first injectable immune checkpoint inhibitor likely won’t make it to the U.S. anytime soon, after the China-approved drug flunked a pivotal trial in a rare cancer, forcing its stateside developer Tracon to explore strategic alternatives.

Fierce podcasts

Don’t miss an episode

The best biopharma M&A deals

In today’s episode of "The Top Line," Fierce Biotech’s Annalee Armstrong and James Waldron discuss what they think are the best and smartest biopharma acquisitions in recent years.

Designing with neurodiversity in mind

A closer look at 'friend-shoring' and the drug shortage challenge

Resources

Whitepaper

An Integrated End-to-End Approach to Antibody Drug Conjugate Development and Manufacturing

In this white paper, Lonza experts delve into the common challenges encountered by ADC developers. They explore new drug product capabilities in relation to cytotoxic drug development and manufacturing, therefore fully completing Lonza’s integrated ADC offering. Further, they discuss how this end-to-end approach can significantly accelerate the timeline to investigational new drug filing and beyond. Read this white paper to learn more.

2024 Life Sciences Industry Outlook

The definitive report on the state of our industry. Readers will gain an understanding of key indicators to monitor, future predictions, and guidance for investors and founders navigating the therapeutic enabling tools and services, healthtech and techbio sectors through 2024 and beyond.

The “Best Practice Organization” & Its Importance for Success in Today’s Biopharma Industry

In a complex industry like biopharma, being a “Best Practice Organization” (BPO) is essential to success. But what is a BPO & how do you build one? This eBook provides the answers.

Sponsored by: Blue Matter, strategic consultants in the life sciences